Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + Metformin

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Cushing's Disease

Conditions

Cushing's Disease, Acromegaly

Trial Timeline

May 23, 2014 → Mar 26, 2018

NCT ID

NCT02060383

About Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + Metformin

Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + Metformin is a approved stage product being developed by Novartis for Cushing's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02060383. Target conditions include Cushing's Disease, Acromegaly.

What happened to similar drugs?

1 of 9 similar drugs in Cushing's Disease were approved

Approved (1) Terminated (1) Active (7)

🔄pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3

🔄Pasireotide sub-cutaneousNovartisPhase 3

🔄osilodrostat + osilodrostat PlaceboNovartisPhase 3

🔄PasireotideNovartisPhase 3

✅Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved

🔄mifepristoneCorcept TherapeuticsPhase 3

🔄MifepristoneCorcept TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02060383	Approved	Completed	May 23, 2014	Mar 26, 2018	Cushing's Disease

Competing Products

18 competing products in Cushing's Disease

See all competitors

Product	Company	Stage	Hype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisolone	AstraZeneca	Phase 2	35
pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mg	Novartis	Phase 3	40
Pasireotide sub-cutaneous	Novartis	Phase 3	40
osilodrostat + osilodrostat Placebo	Novartis	Phase 3	40
Osilodrostat	Novartis	Phase 2	35
Pasireotide	Novartis	Phase 3	40
SOM230 s.c.	Novartis	Phase 2	35
Lu AG13909	Lundbeck	Phase 2	39
Osilodrostat	Recordati	Pre-clinical	23
Pasireotide + Cabergoline + Pasireotide LAR	Recordati	Approved	40
osilodrostat	Recordati	Phase 2	32
Osilodrostat	Recordati	Pre-clinical	27
mifepristone	Corcept Therapeutics	Phase 3	37
CORT125134	Corcept Therapeutics	Phase 2	32
Cushing's syndrome confirmation	Corcept Therapeutics	Pre-clinical	15
Mifepristone	Corcept Therapeutics	Phase 3	37
mifepristone	Corcept Therapeutics	Phase 3	37
mifepristone	Corcept Therapeutics	Phase 3	29